Cell cycle and related protein

Disease Markers

Volumn 23, Issue 5-6, 2007, Pages 433-443

  Farley, John ^a   Ozbun, Laurent ^b   Samimi, Goli ^b   Birrer, Michael J ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biologiomarkers; Gynecologic; Malignancies

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P130; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; VASCULOTROPIN RECEPTOR;

CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 36448962411     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/464712     Document Type: Review

References (57)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward et al., Cancer statistics, 2004, CA Cancer J Clin 54 (2004), 8-29. Notes: CORPORATE NAME: American Cancer Society.
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look et al., Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study, Semin Oncol 24 (1997), S2-13-S2-16.
3. M.A. Bookman, Biologic therapies for gynecologic cancer, Curr Opin Oncol 7 (1995), 478-484.
4. M.A. Bookman, Biological therapy for gynecologic malignancies, Cancer Treat Res 95 (1998), 115-147.
5. A. Berchuck, M.F. Kohler, J.R. Marks, R. Wiseman, J. Boyd and R.C. Bast, Jr., The p53 tumor suppressor gene frequently is altered in gynecologic cancers, Am J Obstet Gynecol 170 (1994), 246-252.
6. G. Casey, M.E. Lopez, J.C. Ramos, S.J. Plummer, M.J. Arboleda, M. Shaughnessy et al., DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies, Oncogene 13 (1996), 1971-1981.
7. G.H. Eltabbakh, J.L. Belinson, A.W. Kennedy, C.V. Biscotti, G. Casey, R.R. Tubbs et al., p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer, Cancer 80 (1997), 892-898.
8. J.P. Geisler, H.E. Geisler, G.A. Miller, M.C. Wiemann, Z. Zhou and W. Crabtree, p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months, Gynecol Oncol 77 (2000), 278-282.
9. M. Baekelandt, G.B. Kristensen, J.M. Nesland, C.G. Trope and R. Holm, Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer, J Clin Oncol 17 (1999), 2061.
10. L.C. Hartmann, K.C. Podratz, G.L. Keeney, N.A. Kamel, J.H. Edmonson, J.P. Grill et al., Prognostic significance of p53 immunostaining in epithelial ovarian cancer, J Clin Oncol 12 (1994), 64-69.
11. L. Havrilesky, M. Darcy, H. Hamdan, R.L. Priore, J. Leon, J. Bell et al., Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study, J Clin Oncol 21 (2003), 3814-3825. Notes: CORPORATE NAME: Gynecologic Oncology Group Study.
12. D. Romagnolo, L.A. Annab, T.E. Thompson, J.I. Risinger, L.A. Terry, J.C. Barrett et al., Estrogen upregulation of BRCA1 expression with no effect on localization, Mol Carcinog 22 (1998), 102-109.
13. C. Wang, A. Horiuchi, T. Imai, S. Ohira, K. Itoh, T. Nikaido et al., Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene, J Pathol 202(2) (2004), 215-223. 0022-3417.
14. R.L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, S. Narod et al., BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study, Cancer Res 60 (2000), 5329-5333.
15. G. D'Andrilli, V. Masciullo, L. Bagella, T. Tonini, C. Minimo, G.F. Zannoni et al., Frequent loss of pRb2/p130 in human ovarian carcinoma, Clin Cancer Res 10 (2004), 3098-3103.
16. G. Peiro, J. Diebold and U. Lohrs, CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression, Am J Clin Pathol 118 (2002), 922-929.
17. T. Tonini, C. Gabellini, L. Bagella, G. D'Andrilli, V. Masciullo, G. Romano et al., pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol, Clin Cancer Res 10 (2004), 8085-8093.
18. P.J. Srivatsa, W.A. Cliby, G.L. Keeney, M.K. Dodson, V.J. Suman, P.C. Roche et al., Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma, Gynecol Oncol 60 (1996), 363-372.
19. D. Fabbro, D. Parkinson and A. Matter, Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2 (2002), 374-381.
20. S. Goel, S. Mani and R. Perez-Soler, Tyrosine kinase inhibitors: a clinical perspective, Curr Oncol Rep 4 (2002), 9-19.
21. C.L. Arteaga, F. Khuri, G. Krystal and S. Sebti, Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer, Semin Oncol 29 (2002), 15-26.
22. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol 20 (2002), 719-726.
23. O.J. Owens, C. Stewart, R.E. Leake and A.M. McNicol, A comparison of biochemical and immunohistochemical assessment of EGFR expression in ovarian cancer, Anticancer Res 12 (1992), 1455-1458.
24. H. Niikura, H. Sasano, S. Sato and A. Yajima, Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors, Int J Gynecol Pathol 16 (1997), 60-68.
25. I. Skirnisdottir, T. Seidal and B. Sorbe, A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging, Int J Gynecol Cancer 14 (2004), 259-270.
26. E.V. Hogdall, L. Christensen, S.K. Kjaer, J. Blaakaer, J.E. Bock, E. Glud et al., Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study, Cancer 98 (2003), 66-73.
27. C.H. Lee, D.G. Huntsman, M.C. Cheang, R.L. Parker, L. Brown, P. Hoskins et al., Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma, Int J Gynecol Pathol 24 (2005), 147-152.
28. P.J. Paley, Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies, Curr Oncol Rep 4 (2002), 165-174.
29. M. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, M. Sliwkowski et al., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene 18 (1999), 2241-2251.
30. Z. Aguilar, R.W. Akita, R.S. Finn, B.L. Ramos, M.D. Pegram, F.F. Kabbinavar et al., Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells, Oncogene 18 (1999), 6050-6062.
31. N. Starling and D. Cunningham, Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions, Curr Opin Oncol 16 (2004), 385-390.
32. R.J. D'Amato, M.S. Loughnan, E. Flynn and J. Folkman, Thalidomide is an inhibitor of angiogenesis, Proc Natl Acad Sci USA 91 (1994), 4082-4085.
33. H. Brustmann, Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis, Gynecol Oncol 95 (2004), 16-22.
34. G.H. Shen, M. Ghazizadeh, O. Kawanami, H. Shimizu, E. Jin, T. Araki et al., Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma, Br J Cancer 83 (2000), 196-203.
35. P.J. Paley, K.A. Staskus, K. Gebhard, D. Mohanraj, L.B. Twiggs, L.F. Carson et al., Vascular endothelial growth factor expression in early stage ovarian carcinoma, Cancer 80 (1997), 98-106.
36. J.H. Farley and M.J. Birrer, Biologic directed therapies in gynecologic oncology, Curr Oncol Rep 5 (2003), 459-467.
37. L. Sui, M. Tokuda, M. Ohno, O. Hatase and T. Hando, The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors, Gynecol Oncol 73 (1999), 202-209.
38. G. Ferrandina, F. Legge, E. Martinelli, F.O. Ranelletti, G.F. Zannoni, L. Lauriola et al., Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters, Br J Cancer 92 (2005), 271-277.
39. F. Barbieri, P. Lorenzi, N. Ragni, G. Schettini, C. Bruzzo, F. Pedulla et al., Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer, Oncology 66 (2004), 310-315.
40. J. Farley, L.M. Smith, K.M. Darcy, E. Sobel, D. O'Connor, B. Henderson et al., Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study, Cancer Res 63 (2003), 1235-1241. Notes: CORPORATE NAME: Gynecologic Oncology Group.
41. M. Shimizu, T. Nikaido, T. Toki, T. Shiozawa and S. Fujii, Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas, Cancer 85 (1999), 669-677.
42. Y. Dong, M.D. Walsh, M.A. McGuckin, B.G. Gabrielli, M.C. Cummings, R.G. Wright et al., Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis, Int J Cancer 74 (1997), 57-63.
43. T. Kusume, H. Tsuda, M. Kawabata, T. Inoue, N. Umesaki, T. Suzuki et al., The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer, Clin Cancer Res 5 (1999), 4152-4157.
44. L. Sui, Y. Dong, M. Ohno, M. Goto, T. Inohara, K. Sugimoto et al., Inverse expression of Cdk4 and p16 in epithelial ovarian tumors, Gynecol Oncol 79 (2000), 230-237.
45. M. Baekelandt, R. Holm, C.G. Trope, J.M. Nesland and G.B. Kristensen, Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study, Clin Cancer Res 5 (1999), 2848-2853.
46. A. Harlozinska, J.K. Bar, M. Montenarh and S. Kartarius, Relations between immunologically different p53 forms, p21(WAF1) and PCNA expression in ovarian carcinomas, Oncol Rep 9 (2002), 1173-1179.
47. G. Ferrandina, A. Stoler, A. Fagotti, F. Fanfani, R. Sacco, A. De Pasqua et al., p21WAF1/CIP1 protein expression in primary ovarian cancer, Int J Oncol 17 (2000), 1231-1235.
48. V. Masciullo, A. Sgambato, C. Pacilio, B. Pucci, G. Ferrandina, J. Palazzo et al., Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer, Cancer Res 59 (1999), 3790-3794.
49. V. Masciullo, G. Ferrandina, B. Pucci, F. Fanfani, S. Lovergine, J. Palazzo et al., p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis, Clin Cancer Res 6 (2000), 4816-4822.
50. J.A. Hurteau, B.M. Allison, S.A. Brutkiewicz, M.G. Goebl, D.K. Heilman, R.M. Bigsby et al., Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer, Gynecol Oncol 83 (2001), 292-298.
51. D.G. Rosen, G. Yang, K.Q. Cai, R.C. Bast, Jr., D.M. Gershenson, E.G. Silva et al., Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer, Clin Cancer Res 11 (2005), 632-637.
52. A.A. Adjei and M. Hidalgo, Intracellular signal transduction pathway proteins as targets for cancer therapy, J Clin Oncol 23 (2005), 5386-5403.
53. M.G. Teneriello, M. Ebina, R.I. Linnoila, M. Henry, J.D. Nash, R.C. Park et al., p53 and Ki-ras gene mutations in epithelial ovarian neoplasms, Cancer Res 53 (1993), 3103-3108.
54. I.N. Mammas, A. Zafiropoulos and D.A. Spandidos, Involvement of the ras genes in female genital tract cancer, Int J Oncol 26 (2005), 1241-1255.
55. D.G. Rosen, L. Wang, A.N. Jain, K.H. Lu, R.Z. Luo, Y. Yu et al., Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival, Clin Cancer Res 10 (2004), 6559-6566.
56. C.Y. Hsu, R. Bristow, M.S. Cha, B.G. Wang, C.L. Ho, R.J. Kurman et al., Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas, Clin Cancer Res 10 (2004), 6432-6436.
57. B.J. Monk, D.C. Choi, G. Pugmire and R.A. Burger, Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer, Gynecol Oncol 96 (2005), 902-905.